Bomanji J, Bouloux P M, Levison D A, Flatman W D, Horne T, Britton K E, Ross G, Besser G M
Eur J Nucl Med. 1987;13(2):86-9. doi: 10.1007/BF00256022.
123I-MIBG is a norepinephrine analogue used for imaging phaeochromocytomas and other paragangliomas. In this study 7 normal volunteers and 31 subjects with high or borderline high plasma catecholamine and urinary metanephrine and VMA levels were investigated. In the normals the uptake by the adrenal medulla was in the range of 0.01%-0.21% of the injected dose at 22 h. In 22 subjects there was no evidence for any paraganglioma, with the uptake by the adrenal medulla in the range of 0.01%-0.22% of the injected dose at 22 h. In nine patients there was evidence of a paraganglioma on imaging which was confirmed on surgery. The uptake by the tumours was in the order of 0.001%-0.14% of the injected dose per gram of tumour tissue. In all nine cases the non-tumorous adrenal medulla could be visualized; the uptake in the adrenals was in the range of 0.01%-0.21% of the injected dose. This study shows that in the presence of elevated plasma catecholamines of tumour origin the unaffected adrenal medullary tissue retains the capacity for 123I-MIBG uptake. In the two cases also studied by adrenal venous sampling, catecholamine release was also within the normal range.
123I-间碘苄胍是一种去甲肾上腺素类似物,用于嗜铬细胞瘤和其他副神经节瘤的成像。在本研究中,对7名正常志愿者和31名血浆儿茶酚胺、尿甲氧基肾上腺素和香草扁桃酸水平高或临界高的受试者进行了调查。在正常受试者中,肾上腺髓质在22小时时的摄取量为注射剂量的0.01%-0.21%。22名受试者未发现任何副神经节瘤,其肾上腺髓质在22小时时的摄取量为注射剂量的0.01%-0.22%。9名患者成像显示有副神经节瘤,手术证实。肿瘤的摄取量约为每克肿瘤组织注射剂量的0.001%-0.14%。在所有9例病例中,非肿瘤性肾上腺髓质均可显影;肾上腺的摄取量为注射剂量的0.01%-0.21%。本研究表明,在存在肿瘤源性血浆儿茶酚胺升高的情况下,未受影响的肾上腺髓质组织保留摄取123I-间碘苄胍的能力。在另外两例也通过肾上腺静脉采血研究的病例中,儿茶酚胺释放也在正常范围内。